Researchers Database

matsuzono kousuke

    InternalMedicineNeurology Assistant Professor
Last Updated :2021/11/23

Researcher Information

Degree

  • Research Associate(Okayama University)

Research funding number

  • 80809070

J-Global ID

Research Interests

  • Prion   Spinocerebellar ataxia   iPS cell   Stroke   Neurology   

Research Areas

  • Life sciences / Neurology

Academic & Professional Experience

  • 2021/04 - Today  Jichi Medical UniversityDivision of Neurology, Department of MedicineAssistant Professor
  • 2017/04 - 2021/03  Jichi Medical UniversityDivision of Neurology, Department of MedicineResearch Associate
  • 2015/04 - 2017/03  Center for iPS Cell Research and Application, Kyoto UniversityInoue Laboratory, Department of Cell Growth and DifferentiationSpecial Research Student
  • 2014/04 - 2015/03  Okayama UniversityDepartment of NeurologyMedical Staff
  • 2013/04 - 2014/03  Nataional Cerebral and Cardiovascular CenterDivision of Cerebrovascular Medicine and NeurologyResident
  • 2012/10 - 2013/03  Okayama Medical CenterDepartment of NeurologyResident
  • 2012/04 - 2012/09  Kurashiki Heisei HospitalDepartment of NeurologyMedical Staff
  • 2011/04 - 2012/03  Okayama UniversityDepartment of NeurologyResident
  • 2009/04 - 2011/03  Kakunodate General HospitalResident

Education

  • 2015/04 - 2017/03  Kyoto University  Center for iPS Cell Research and Application  Inoue Laboratory
  • 2014/04 - 2017/03  Okayama University  大学院  Doctor's degree
  • 2003/04 - 2009/03  Kagoshima University  Department of Medicine  医学科
  • 2000/04 - 2003/03  La Salle High School

Published Papers

  • Kosuke Matsuzono, Tomoya Yagisawa, Keisuke Ohtani, Yohei Ishishita, Takashi Yamaguchi, Takafumi Mashiko, Tadashi Ozawa, Reiji Koide, Ryota Tanaka, Kensuke Kawai, Shigeru Fujimoto
    The Journal of international medical research 49 (8) 3000605211035197 - 3000605211035197 2021/08 
    Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma, but its diagnosis is challenging in some cases. A brain biopsy is the gold standard for diagnosing PCNSL, but its invasiveness can be problematic. Thus, noninvasive imaging examinations have been developed for the pre-surgical diagnosis of PCNSL, including gadolinium-enhanced magnetic resonance imaging (MRI), 123I-N-isopropyl-p-iodoamphetamine single-photon emission computed tomography (123I-IMP SPECT), and positron emission tomography with 18F-fluorodeoxyglucose (18F-FDG PET). Here, we report the case of a 71-year-old woman with negative imaging findings for PCNSL, but who was diagnosed with PCNSL by a brain biopsy and histological analysis. Her imaging results were negative for gadolinium-enhanced cranial MRI, with low uptake in 123I-IMP SPECT and hypometabolism in 18F-FDG PET. However, a stereotactic brain biopsy from an abnormal lesion revealed that many round cells had infiltrated into the brain. Moreover, many infiltrating cells were positive for cluster of differentiation (CD)20 and CD79a, and proliferation marker protein Ki-67-positive cells accounted for nearly 80% of all cells. Based on these results, our final pathological diagnosis was PCNSL. The present case highlights the possibility of a PCNSL diagnosis even when all imaging-related examinations display negative results.
  • Kosuke Matsuzono, Masayuki Suzuki, Kumiko Miura, Tadashi Ozawa, Takafumi Mashiko, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021/07 
    BACKGROUND: Although the relationship between amyotrophic lateral sclerosis (ALS) and cervical spondylotic myelopathy (CSM) is important, data relating to CSM complications in ALS remain lacking. PURPOSE: We aimed to investigate and validate the spinal cord conditions of ALS patients. MATERIALS AND METHODS: We recruited all patients diagnosed with ALS, Parkinson's disease (PD), or chronic inflammatory demyelinating polyneuropathy (CIDP) who were admitted to our department from April 1, 2017, to March 31, 2020. We analyzed the cervical or thoracolumbar magnetic resonance imaging (MRI) scans of these 128 patients. Data relating to spondylosis, cord compression, spinal canal diameter, spinal cord diameter, and the closest distance between the cervical spinal canal and cord were validated using MRI. RESULTS: Of the 128 patients, 52 had ALS, 48 had PD, and 28 had CIDP. The proportions of both cervical spondylosis and cervical cord compression were highest in the ALS group compared with the other patient groups (p < 0.05). The proportion of cervical spondylosis in ALS patients reached 38.3%, and that of cervical cord compression reached 53.2%. The closest distance between the cervical spinal canal and cord was also significantly smaller in ALS patients compared with CIDP patients (p < 0.05). In contrast to the cervical cord findings, there were no significant differences in the thoracolumbar cord between ALS patients and the other patient groups. CONCLUSIONS: Of the three disease groups, the proportion of CSM was highest in ALS patients. Furthermore, cervical cord conditions were significantly more crowded in the ALS patients than in the other patient groups.
  • Hiroyuki Honda, Kosuke Matsuzono, Kota Satoh, Masayoshi Fujisawa, Satoshi O Suzuki, Chiaki Furuyama, Tetsuyuki Kitamoto, Shigeru Fujimoto, Koji Abe, Toru Iwaki
    European journal of neurology 28 (6) 2133 - 2137 2021/06 
    BACKGROUND AND PURPOSE: To investigate prion protein (PrP) deposits in cutaneous tissues of patients of glycosylphosphatidylinositol (GPI)-anchorless prion diseases with neuropathy. METHODS: Cutaneous tissue samples from three patients with GPI-anchorless prion diseases were obtained, two cutaneous biopsy samples from the lower leg of Case 1 (Y162X) and Case 3 (D178fs25), and a cutaneous sample taken from the abdomen during an autopsy of Case 2 (D178fs25). We performed immunohistochemistry for PrP to look for abnormal PrP deposits. RESULTS: PrP deposits were observed in the dermal papilla, the sweat glands, the hair follicles, the arrector pili muscles, and peripheral nerves of all examined cases of GPI-anchorless prion disease with neuropathy. The abnormal PrP accumulation was frequently localized at the basement membrane, and colocalized with laminin. CONCLUSION: Immunohistochemical detection of PrP in cutaneous samples could be used to definitively diagnose GPI-anchorless PrP disease with neuropathy.
  • Kosuke Matsuzono, Theerawat Kumutpongpanich, Kana Kubota, Takafumi Okuyama, Kohei Furuya, Tomoya Yagisawa, Akie Horikiri, Takeshi Igarashi, Kumiko Miura, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Hayato Shimizu, Yasushi Imai, Kazuomi Kario, Ichizo Nishino, Shigeru Fujimoto
    Internal medicine (Tokyo, Japan) 2021/02 
    Cardiac involvement has recently been the focus of sporadic late-onset nemaline myopathy (SLONM). However, right ventricular failure and pulmonary hypertension, in addition to repetitive cardiac arrest, are noteworthy characteristics of SLONM. We herein report a 66-year-old woman with SLONM whose main symptoms were cardiac arrest, right ventricular failure, and pulmonary hypertension. Despite permanent pacemaker replacement, cardiac arrest occurred repetitively, and even with continuous positive airway pressure, right ventricular failure and pulmonary hypertension persisted. The patient was finally diagnosed with SLONM by a muscle biopsy. Our case suggests the possibility of cardiovascular involvement in SLONM, especially right ventricular failure and pulmonary hypertension.
  • Kosuke Matsuzono, Younhee Kim, Hiroyuki Honda, Yuhei Anan, Masato Tsunoda, Yusuke Amano, Noriyoshi Fukusima, Toru Iwaki, Tetsuyuki Kitamoto, Shigeru Fujimoto
    The American journal of gastroenterology 2020/11
  • Masayuki Suzuki, Kohei Furuya, Misato Ozawa, Kumiko Miura, Tadashi Ozawa, Kosuke Matsuzono, Takafumi Mashiko, Reiji Koide, Shigeru Fujimoto, Ryota Tanaka
    Journal of atherosclerosis and thrombosis 2020/09 
    AIM: Aortic arch atherosclerosis, particularly complex aortic arch plaques (CAPs), is an important source of cerebral emboli. CAPs and atrial fibrillation (AF) often co-exist; however, the prevalence and risk of CAPs in acute ischemic stroke patients with AF is unclear. METHODS: In patients with acute ischemic stroke with non-valvular AF admitted to Jichi Medical University Hospital during April 2016 to September 2019, we retrospectively evaluated the presence of CAPs on transesophageal echocardiography (TEE). RESULTS: CAPs were observed in 41 (38.7 %) of 106 patients with non-valvular AF. Older age, diabetes mellitus, chronic kidney disease, low high-density lipoprotein cholesterol (HDL-C) levels, higher levels of glycohemoglobin A1c (HbA1c), higher CHADS2 and CHA2DS2-VASc scores, and intracranial or carotid artery stenosis were more frequently observed in CAPs-positive than in CAPs-negative patients. In multivariable analyses, older age (odds ratio [OR]: 1.2 per year increase; 95% confidence interval [CI]: 1.07-1.24; P<0.0001), diabetes mellitus (OR: 4.7; 95%CI: 1.27-17.35; P<0.05), and low HDL-C (OR: 0.95 per 1 mg/dl increase; 95%CI: 0.92-0.99; P <0.01) were independent risk factors for CAPs. The prevalence of CAPs was age-dependent, and there was a significantly higher risk in patients aged either 75-84 years or >84 years than in those aged <65 (OR: 7.6; 95%CI: 1.50-38.62, and OR: 32.1; 95%CI: 5.14-200.11, respectively). CONCLUSIONS: Even in patients with ischemic stroke with non-valvular AF, concomitant CAPs should be considered in older individuals and those who have diabetes or low HDL-C.
  • Kosuke Matsuzono, Kumiko Miura, Tadashi Ozawa, Takafumi Mashiko, Shigeru Fujimoto
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 41 (9) 2625 - 2627 2020/09 [Refereed][Not invited]
  • Kosuke Matsuzono, Kohei Furuya, Takafumi Mashiko, Tadashi Ozawa, Kumiko Miura, Masayuki Suzuki, Misato Ozawa, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Journal of the neurological sciences 415 116924 - 116924 2020/08 
    OBJECTIVES: Magnetic resonance angiography (MRA), three-dimensional computed tomography angiography, and cerebral angiography may be used to assess intracranial vertebrobasilar stenosis. However, these examinations cannot be performed at patients' bedsides. Our purpose was to develop a new bedside method to assess intracranial vertebrobasilar arterial stenosis. METHODS: We developed the new method using carotid duplex ultrasonography combined with the head-up test. A total of 141 subjects admitted between June 1, 2017 and March 31, 2019 were enrolled in this study. We calculated vertebral arterial peak systolic velocities (PSVs), end-diastolic velocities (EDVs), and mean velocities (MVs) at 0°, 16°, and 30° head-up angles. Vertebrobasilar arterial stenosis was confirmed using MRA. RESULTS: We excluded 28 subjects and included data for 113 subjects and 226 vessels in the final analysis. Cervical vertebral arterial PSV, EDV, and MV gradually decreased from 0° to 30° only in stenotic intracranial vertebral arteries. Sensitivity (probability of detection) was 75.5% and specificity (true negative rate) was 79.7% when EDV at the 30° head-up angle decreased ≥19.5% from the initial 0° head-up angle. Specificity was better (86.4%; sensitivity: 69.4%) when EDV was <9.1 cm/s at the 30° head-up angle. CONCLUSION: This new method easily detects intracranial vertebrobasilar arterial stenosis.
  • Hikaru Watanabe, Reiji Koide, Misato Yokose Ozawa, Younhee Kim, Kumiko Miura, Tadashi Ozawa, Kosuke Matsuzono, Takafumi Mashiko, Ryota Tanaka, Yusuke Amano, Katsuya Nagatani, Kojiro Sato, Shigeru Fujimoto
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 41 (7) e889-e890  2020/08
  • Kosuke Matsuzono, Takafumi Mashiko, Tadashi Ozawa, Kumiko Miura, Masayuki Suzuki, Kohei Furuya, Misato Ozawa, Yuhei Anan, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Tomoaki Kameda, Shigeru Fujimoto
    Journal of thrombosis and thrombolysis 2020/06 
    The treatment of ischemic stroke has recently witnessed dramatic developments. However, there are limited data on ischemic stroke characteristics in aged patients. As part of the South Tochigi Acute Ischemic Stroke Registry, we prospectively enrolled 636 consecutive acute ischemic stroke patients (within 7 days after the onset) who were ≥ 60 years of age and who were admitted to two independent institutes from April 1, 2016 to February 28, 2019. We analyzed three groups divided by age: early-aged (60-69 years), middle-aged (70-79 years), and oldest-aged (≥ 80 years). From the 636 subjects, 194 were early-aged, 215 were middle-aged, and 227 were oldest-aged. There were significant differences in the ischemic stroke subtypes in each aging group (p < 0.01). The proportion of cardioembolism was 22.2% in early-aged, 27.4% in middle-aged, and 41.4% in the oldest-aged patients. The proportion of patients with a modified Rankin Scale of 0-2 at 1 year after onset decreased to 42.2% in middle-aged and 17.8% in oldest-aged with cardioembolic ischemic stroke. The proportion of patients receiving anticoagulation therapy before admission was 25.6% (36.7% of atrial fibrillation [AF]) in early-aged, 39.0% (52.3% of AF) in middle-aged, and 18.1% (21.0% of AF) in oldest-aged patients (p < 0.001). Our study reports characteristics of clinical ischemic stroke in an aging population. The assessment of cardiogenic embolism is important for an aging population.
  • Kosuke Matsuzono, Kohei Furuya, Takeshi Igarashi, Akie Horikiri, Takamasa Murosaki, Daekwan Chi, Yuichi Toyama, Kumiko Miura, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Journal of thrombosis and thrombolysis 49 (4) 681 - 684 2020/05 [Refereed][Not invited]
     
    Cerebral amyloid angiopathy-related inflammation is a syndrome of reversible encephalopathy with cerebral amyloid angiopathy, however the pathology is not well understood. We clear a part of the pathology through the first case of an 80-year-old man with cerebral amyloid angiopathy-related inflammation induced by relapsing polychondritis (RP) analysis. An 80-year-old man was diagnosed with RP by auricular cartilage biopsy. Almost no abnormality including intracranial microbleeding was detected by cranial magnetic resonance image (MRI) at diagnosis. However, he developed a headache and hallucination after five months. Seven-month cranial MRI showed novel, multiple, intracranial microbleeding, especially in the bilateral but asymmetry posterior, temporal, and parietal lobes. 123I-N-isopropyl-p-iodoamphetamine single-photon emission computed tomography showed increased cerebral blood flow in the bilateral posterior lobes. After treatment, both of his neurological symptoms and increased cerebral blood flow improved to mild. Photon emission computed tomography using Pittsburgh compound B (PiB) for evaluation of brain amyloidosis at 12 months after onset showed an amyloid deposit in the bilateral frontal lobes, but a lack of uptake corresponded to the RP lesions. Our case suggests that inflammation coupled with an amyloid deposit, induced the multiple intracranial bleeding, and resulted in the lack of PiB uptake. Findings from our case show that inflammation including excess blood flow coupled with an amyloid deposit synergistically facilitate intracranial bleeding.
  • Kosuke Matsuzono, Kohei Furuya, Azusa Karube, Akie Horikiri, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Journal of the neurological sciences 411 116708 - 116708 2020/04 [Refereed][Not invited]
  • Kosuke Matsuzono, Masayuki Suzuki, Shigeru Fujimoto
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 41 (4) 969 - 971 2020/04 [Refereed][Not invited]
  • Kosuke Matsuzono, Takafumi Mashiko, Tadashi Ozawa, Kumiko Miura, Masayuki Suzuki, Kohei Furuya, Misato Ozawa, Yuhei Anan, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Psychiatry and clinical neurosciences 74 (4) 279 - 280 2020/04 [Refereed][Not invited]
  • Miyu Usui, Tadashi Ozawa, Younhee Kim, Takafumi Mashiko, Kosuke Matsuzono, Keiko Maruyama, Koichi Kokame, Rie Usui, Reiji Koide, Shigeru Fujimoto
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 40 (1) 135 - 136 0144-3615 2020/01 [Refereed][Not invited]
  • Tadashi Ozawa, Ryota Tanaka, Risa Nagaoka, Yuhei Anan, Younhee Kim, Kosuke Matsuzono, Takafumi Mashiko, Reiji Koide, Haruo Shimazaki, Keisuke Ohtani, Yusuke Amano, Kensuke Kawai, Shigeru Fujimoto
    Data in brief 27 104648 - 104648 2019/12 [Refereed][Not invited]
     
    Data presented in this article are related to our article entitled "Unilateral posterior reversible encephalopathy syndrome: A case report" [1]. Cases of Posterior Reversible Encephalopathy Syndrome (PRES) involving unilateral lesions are very rare. We searched the PubMed database using keywords such as PRES, unilateral, and asymmetric and found a small number of cases to include in our review. We summarized the characteristics of these reported cases of unilateral PRES, including our case.
  • Tadashi Ozawa, Ryota Tanaka, Risa Nagaoka, Yuhei Anan, Younhee Kim, Kosuke Matsuzono, Takafumi Mashiko, Reiji Koide, Haruo Shimazaki, Keisuke Ohtani, Yusuke Amano, Kensuke Kawai, Shigeru Fujimoto
    Clinical neurology and neurosurgery 185 105493 - 105493 0303-8467 2019/10 [Refereed][Not invited]
  • Kosuke Matsuzono, Makiko Mieno, Shigeru Fujimoto
    Nutrition journal 18 (1) 53 - 53 2019/09 [Refereed][Not invited]
     
    BACKGROUND: The association between stroke and nutrition has recently been investigated. However, the association between diet and stroke in Japan has not been clarified. We hypothesized that there may be an association between consumption of ramen and stroke mortality. Therefore, we investigated the association between the prevalence of ramen restaurants and stroke mortality in Japanese prefectures. METHODS: We used Pearson's correlation coefficients to evaluate associations between the prevalence of each of four restaurant types (ramen, fast food, French or Italian, and udon or soba) and age- and sex-adjusted stroke mortality rates in each prefecture. We also investigated correlations between acute myocardial infarction and the prevalence of each type of restaurant as a control. We obtained age- and sex-adjusted stroke mortality rates and the acute myocardial infarction mortality rate in each prefecture from the 2017 Trends in National Health published in Japan. Data on the number of restaurants of each type in each prefecture were obtained from the database of the Nippon Telegraph and Telephone Corporation. RESULTS: The prevalence of ramen restaurants, but not of other restaurant types, positively correlated with stroke mortality in both men and women (r > 0.5). We found no correlation between ramen restaurant prevalence and mortality from acute myocardial infarction. CONCLUSION: The prevalence of ramen restaurants in Japanese prefectures has a significant correlation with the stroke mortality rate.
  • Miyu Usui, Takafumi Mashiko, Masuko Tsuda, Masayuki Suzuki, Kosuke Matsuzono, Tadashi Ozawa, Yonhee Kim, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 28 (7) e98-e99 - e99 1052-3057 2019/07 [Refereed][Not invited]
     
    Isolated vertigo is an important symptom of posterior circulation stroke. It has been reported that 11.3% of patients with isolated vertigo have a stroke and that most lesions are located in the cerebellum, particularly in the posterior inferior cerebellar artery. We report the case of a 63-year-old man with multiple atherosclerotic risk factors and atrial fibrillation who showed repeated episodes of isolated vertigo. His repeated vertigo was short-lasting and was often triggered by body position, mimicking benign paroxysmal positional vertigo. Cranial computed tomography on the third hospital day showed left cerebellar infarction within the territory of the posterior inferior cerebellar artery. The vertigo was ameliorated on the fifth hospital day and warfarin was prescribed for secondary prevention. Clinicians should pay special attention to cases in which a patient presents isolated vertigo, even if it shows transient recurrence or is triggered by a positional change, especially in patients with multiple cerebrovascular risk factors.
  • Kosuke Matsuzono, Masamichi Baba, Goro Imai, Hiroaki Imai, Shigeru Fujimoto
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 40 (6) 1291 - 1294 1590-1874 2019/06 [Refereed][Not invited]
  • Kosuke Matsuzono, Tadashi Ozawa, Keisuke Yoshikawa, Susumu Kusunoki, Shigeru Fujimoto
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 40 (4) 891 - 893 1590-1874 2019/04 [Refereed][Not invited]
  • Kosuke Matsuzono, Lisa Nagaoka, Masayuki Suzuki, Younhee Kim, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Shigeru Fujimoto
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 28 (4) e24-e26 - e26 1052-3057 2019/04 [Refereed][Not invited]
     
    Fatalities following intravenous recombinant tissue-type plasminogen activator therapy have been reported. Major fatal complications following intravenous recombinant tissue-type plasminogen activator therapy include intracranial hemorrhage, aortic dissection, and extracranial bleeding. However, the possibility that intravenous recombinant tissue-type plasminogen activator therapy itself paradoxically induces synchronized multiple cerebral novel infarctions has never been considered. We herein report the first case of bilateral internal carotid artery infarction with onset seizure following intravenous recombinant tissue-type plasminogen activator therapy for a vertebral-basilar artery infarction. A 75-year-old man was transferred to our hospital and diagnosed with acute ischemic stroke in the basilar artery. His National Institute of Health Stroke Scale score was 4. The intravenous recombinant tissue-type plasminogen activator therapy was initiated 234 minutes after stroke onset because no contraindications were present. Almost 2 hours after the intravenous recombinant tissue-type plasminogen activator therapy, the patient suddenly fell into a deep coma with generalized convulsions. A huge secondary infarction was found in the bilateral anterior circulation territories, and he died 7 days after stroke onset. This case alerts clinicians to the possibility of synchronized multiple cerebral infarctions following intravenous recombinant tissue-type plasminogen activator therapy as a dangerous complication in patients with multiple severe stenoses in the cerebral arteries.
  • Kosuke Matsuzono, Kohei Furuya, Akie Horikiri, Kumiko Miura, Younhee Kim, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Journal of the neurological sciences 397 31 - 33 0022-510X 2019/02 [Refereed][Not invited]
  • Kosuke Matsuzono, Masayuki Suzuki, Kohei Furuya, Dan Tomomasa, Younhee Kim, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Ryota Tanaka, Shigeru Fujimoto
    Journal of the neurological sciences 393 113 - 115 0022-510X 2018/10 [Refereed][Not invited]
  • Misato Yokose, Kohei Furuya, Masayuki Suzuki, Tadashi Ozawa, Younhee Kim, Kumiko Miura, Kosuke Matsuzono, Takafumi Mashiko, Mari Tada, Reiji Koide, Haruo Shimazaki, Tohru Matsuura, Shigeru Fujimoto
    Neuro-ophthalmology (Aeolus Press) 42 (5) 309 - 311 0165-8107 2018/10 [Refereed][Not invited]
     
    Vertical gaze palsy is rarely a neurological symptom, although it has been observed in some cases. Here, we report the case of a patient presenting with complete upward and downward gaze palsy. In this case, a small lesion in the left rostral midbrain was observed on diffusion-weighted magnetic resonance (MR) images, and the lesion was considered to cause the ocular symptom. We consider that vertical gaze palsy is an important clue to an accurate topical diagnosis of a brain lesion.
  • Kosuke Matsuzono, Masayuki Suzuki, Naoto Arai, Younhee Kim, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Shigeru Fujimoto
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 27 (7) e132-e134 - e134 1052-3057 2018/07 [Refereed][Not invited]
     
    Some stroke patients with the acute aortic dissection receiving thrombolysis treatment resulted in fatalities. Thus, the concurrent acute aortic dissection is the contraindication for the intravenous recombinant tissue-type plasminogen activator. However, the safety and the effectiveness of the intravenous recombinant tissue-type plasminogen activator therapy are not known in patients with stroke some days after acute aortic dissection treatment. Here, we first report a case of a man with a cardioembolism due to the nonvalvular atrial fibrillation, who received the intravenous recombinant tissue-type plasminogen activator therapy 117 days after the traumatic Stanford type A acute aortic dissection operation. Without the intravenous recombinant tissue-type plasminogen activator therapy, the prognosis was expected to be miserable. However, the outcome was good with no complication owing to the intravenous recombinant tissue-type plasminogen activator therapy. Our case suggests the effectiveness and the safety of the intravenous recombinant tissue-type plasminogen activator therapy to the ischemic stroke some days after acute aortic dissection treatment.
  • Kosuke Matsuzono, Naoto Arai, Masayuki Suzuki, Younhee Kim, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Tohru Matsuura, Shigeru Fujimoto
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 27 (6) e110-e112 - e112 1052-3057 2018/06 [Refereed][Not invited]
     
    Although foam sclerotherapy to varicose veins is now a popular treatment because of its high efficacy and safety, some neurologic complications have recently been reported. Presently, the effectiveness and safety of intravenous recombinant tissue-type plasminogen activator therapy to stroke following foam sclerotherapy remain unclear. Here, we report the case of a 68-year-old woman whose ischemic symptoms following foam sclerotherapy were treated by intravenous recombinant tissue-type plasminogen activator. After she was admitted, the venous thrombosis in her right soleus vein and a patent foramen ovale causing the right-to-left shunt were revealed. Thus, we diagnosed the ischemic symptoms were due to paradoxical embolism following foam sclerotherapy. After intravenous recombinant tissue-type plasminogen activator therapy, there was no complication and the outcome was good. Our case suggests the effectiveness and the safety of intravenous recombinant tissue-type plasminogen activator therapy to paradoxical embolism following foam sclerotherapy.
  • Kentaro Deguchi, Kosuke Matsuzono, Yumiko Nakano, Syoichiro Kono, Kota Sato, Shoko Deguchi, Katsuyuki Tanabe, Nozomi Hishikawa, Yasuyuki Ota, Toru Yamashita, Kiyoe Ohta, Masakatsu Motomura, Koji Abe
    Internal medicine (Tokyo, Japan) 57 (10) 1455 - 1458 0918-2918 2018/05 [Refereed][Not invited]
     
    A 37-year-old man with anti-muscle-specific tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) presented with subacute progressive dysphagia and muscle weakness of the neck and bilateral upper extremities. Conventional immune-suppressive treatments and high-dose intravenous immunoglobulin were ineffective. He then displayed repeated exacerbations and remissions over the course of two years, despite two to four sessions of plasma exchange (PE) every two months. The patient was successfully treated with outpatient periodic weekly blood purification therapy with alternative PE and double-filtration plasmapheresis using an internal shunt. This case report suggests the benefits of blood purification therapy with an internal shunt against anti-MuSK antibody-positive MG.
  • Kosuke Matsuzono, Keiko Imamura, Nagahisa Murakami, Kayoko Tsukita, Takuya Yamamoto, Yuishin Izumi, Ryuji Kaji, Yasuyuki Ohta, Toru Yamashita, Koji Abe, Haruhisa Inoue
    Molecular therapy. Nucleic acids 8 211 - 219 2017/09 [Refereed][Not invited]
     
    Spinocerebellar ataxia type 36 is a late-onset, slowly progressive cerebellar syndrome with motor neuron degeneration that is caused by expansions of a hexanucleotide repeat (GGCCTG) in the noncoding region of NOP56 gene, with a histopathological feature of RNA foci formation in postmortem tissues. Here, we report a cellular model using the spinocerebellar ataxia type 36 patient induced pluripotent stem cells (iPSCs). We generated iPSCs from spinocerebellar ataxia type 36 patients and differentiated them into neurons. The number of RNA-foci-positive cells was increased in patient iPSCs and iPSC-derived neurons. Treatment of the 2'-O, 4'-C-ethylene-bridged nucleic acid antisense oligonucleotides (ASOs) targeting NOP56 pre-mRNA reduced RNA-foci-positive cells to ∼50% in patient iPSCs and iPSC-derived neurons. NOP56 mRNA expression levels were lower in patient iPSCs and iPSC-derived neurons than in healthy control neurons. One of the ASOs reduced the number of RNA-foci-positive cells without altering NOP56 mRNA expression levels in patient iPSCs and iPSC-derived neurons. These data show that iPSCs from spinocerebellar ataxia type 36 patients can be useful for evaluating the effects of ASOs toward GGCCTG repeat expansion in spinocerebellar ataxia type 36.
  • Yasuyuki Ohta, Toru Yamashita, Nozomi Hishikawa, Kota Sato, Kosuke Matsuzono, Keiichiro Tsunoda, Noriko Hatanaka, Mami Takemoto, Toshihiko Takemi, Kazuhiro Takamatsu, Koji Abe
    Journal of the neurological sciences 373 216 - 222 0022-510X 2017/02 [Refereed][Not invited]
     
    OBJECTIVE: To evaluate a potential multisystem involvement of neurodegeneration in Asidan, in addition to cerebellar ataxia and signs of motor neuron disease. METHODS: We compared the new Asidan patients and those identified in previous studies with Parkinson's disease (PD, n=21), and progressive supranuclear palsy (PSP, n=13) patients using 123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy (Asidan, DAT: n=10; MIBG: n=15). RESULTS: Both the PD and PSP groups served as positive controls for DAT decline. The PD and PSP groups served as a positive and negative control, respectively, of MIBG decline in the early phase H/M ratio. Of the Asidan patients, 60.0% showed DAT decline without evident parkinsonian features and 6.7% showed impaired MIBG in only the delayed phase H/M ratio. Combined with a normal range of the early phase H/M ratio, this phenotype was newly named Declined DAT Without Evident Parkinsonism (DWEP). INTERPRETATION: The results of present study including DWEP suggest a wider spectrum of neurodegeneration for extrapyramidal and autonomic systems in Asidan patients than expected, involving cerebellar, motor system and cognitive functioning.
  • Hiroyuki Honda, Kosuke Matsuzono, Soichiro Fushimi, Kota Sato, Satoshi O Suzuki, Koji Abe, Toru Iwaki
    Journal of neuropathology and experimental neurology 75 (11) 1008 - 1019 0022-3069 2016/11 [Refereed][Not invited]
     
    Prion protein (PrP) has 2 glycosylated sites and a glycosylphosphatidylinositol (GPI) anchor on the C-terminal. Reports on genetic prion disease with GPI anchorless PrP are very limited. In this study, we characterized the molecular alterations of mutated PrP in a 37-year-old female autopsy case with a recently identified PRNP mutation involving a 2-bp deletion in codon 178 that results in a premature stop codon mutation in codon 203. Postmortem examination revealed numerous irregularly shaped coarse PrP deposits and multicentric plaques in the brain that were mainly comprised of C-terminal deleted abnormal PrP primarily derived from the mutant allele. Additionally, abnormal PrP deposits were detected in almost all other examined organs. PrP was mainly deposited in peripheral nerves, smooth muscles, and blood vessels in non-CNS tissues. Western blot analysis after proteinase K treatment showed protease-resistant PrP (PrPres) signals with a molecular weight of 9 kDa; weak PrPres smear signals of 9 to ∼80 kDa were also noted. Gel filtration revealed that PrPres oligomers were mainly composed of the PrP fragments. In conclusion, the mutated PrP lacking that GPI anchor was truncated shortly and deposited in almost every examined organ.
  • Ryo Tokuchi, Nozomi Hishikawa, Kosuke Matsuzono, Yoshiki Takao, Yosuke Wakutani, Kota Sato, Syoichiro Kono, Yasuyuki Ohta, Kentaro Deguchi, Toru Yamashita, Koji Abe
    Geriatrics & gerontology international 16 (4) 440 - 5 1444-1586 2016/04 [Refereed][Not invited]
     
    AIM: The aim of the present study was to compare the effects of a galantamine only therapy and a combination therapy with galantamine plus ambulatory cognitive rehabilitation for Alzheimer's disease patients. METHODS: For this retrospective cohort study, we enrolled 86 patients with Alzheimer's disease, dividing them into two groups - a galantamine only group (group G, n = 45) and a combination with galantamine plus ambulatory rehabilitation group (group G + R, n = 41). The present cognitive rehabilitation included a set of physical therapy, occupational therapy and speech therapy for 1-2 h once or twice a week. We compared the Mini-Mental State Examination and Frontal Assessment Battery for cognitive assessment, and Geriatric Depression Scale, Apathy Scale, and Abe's Behavioral and Psychological Symptoms of Dementia score for affective assessment in two groups over 6 months. RESULTS: The baseline Mini-Mental State Examination score was 20.2 and 18.7 in groups G and G + R, respectively. Other baseline data (Frontal Assessment Battery, Geriatric Depression Scale, Apathy Scale, and Abe's Behavioral and Psychological Symptoms of Dementia) were not different between the two groups. Although group G kept all the scores stable until 6 months of the treatment, the Apathy Scale score showed a significant improvement in group G + R as early as 3 months, followed by the Mini-Mental State Examination and Frontal Assessment Battery improvements at 6 months (*P = 0.04 and *P = 0.02, respectively). The Geriatric Depression Scale and Abe's Behavioral and Psychological Symptoms of Dementia did not show any changes. CONCLUSION: The combination therapy of galantamine plus ambulatory cognitive rehabilitation showed a superior benefit both on cognitive and affective functions than galantamine only therapy in Alzheimer's disease patients.
  • Kosuke Matsuzono, Koji Abe, Haruhisa Inoue
    Nihon rinsho. Japanese journal of clinical medicine 74 (3) 443 - 50 0047-1852 2016/03 [Refereed][Not invited]
     
    Recent developments in induced pluripotent stem cell (iPSC) technology have facilitated, and have contributed to overcome the difficulty of modeling dementia caused by Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD), etc. The following models using iPSCs were reported: the pathophysiology caused by gene mutations such as presenilin or amyloid β precursor protein in AD, α-synuclein in DLB, and microtubule-associated protein tau, fused in sarcoma, progranulin, or chromosome 9 open reading frame 72 in FTLD, anti-AD drug screening, sortilin-related receptor L 1 haplotype influence in sporadic AD, and amyloid β secretion in Down syndrome. Patient-specific iPSC could be expected to reveal the disease pathology and lead to drug discoveries for dementia patients.
  • Kosuke Matsuzono, Nozomi Hishikawa, Yoshiki Takao, Yosuke Wakutani, Toru Yamashita, Kentaro Deguchi, Koji Abe
    Geriatrics & gerontology international 16 (2) 200 - 4 1444-1586 2016/02 [Refereed][Not invited]
     
    OBJECTS: Alzheimer's disease (AD) is one of the most important diseases in aging society, and non-drug therapy might be an alternative therapeutic approach. Thus, we evaluated the add-on effect of cognitive rehabilitation on AD patients under donepezil treatment. METHODS: We retrospectively analyzed 55 AD patients with a Mini-Mental State Examination score of 15-25, dividing them into two groups depending on whether they were receiving ambulatory cognitive rehabilitation (group D + R, n = 32) or not (group D, n = 23) in Kurashiki Heisei Hospital over 1 year. The present cognitive rehabilitation included physical therapy, occupational therapy and speech therapy for 1-2 h once or twice a week. RESULTS: Between group D and group D + R, there was no significant difference in baseline data, such as age, Mini-Mental State Examination score, periventricular hyperintensity on magnetic resonance imaging, deep white matter hyperintensity on magnetic resonance imaging or donepezil dose (4.1 mg/day). At 1 year later, however, the Mini-Mental State Examination score improved only in group D + R from 21.7 to 24.0 (**P < 0.001), whereas that of group D remained at 21.5 with both groups of donepezil 5.0 mg/day. CONCLUSION: The combination of cognitive rehabilitation plus a choline esterase inhibitor donepezil showed a better effect for the cognitive function of AD patients than drug only therapy at 1 year.
  • K Matsuzono, H Honda, K Sato, R Morihara, K Deguchi, N Hishikawa, T Yamashita, S Kono, Y Ohta, T Iwaki, K Abe
    European journal of neurology 23 (1) 196 - 200 1351-5101 2016/01 [Refereed][Not invited]
     
    BACKGROUND AND PURPOSE: A novel TYPE of prion disease associated mainly with autonomic-sensory polyneuropathy was reported by us previously. METHODS: Here the autopsy pathology for patient 1 (the sister) and the clinical characteristics of her younger brother (patient 2) are newly reported. Polymerase chain reaction based restriction fragment length polymorphism analysis of the prion protein gene (PRNP) was performed on both patients and their father (normal control). RESULTS: Polymerase chain reaction based restriction fragment length polymorphism analysis revealed a 2-bp deletion (CT) in codon 178 that causes an additional variable 25 amino acids at the C terminal, from the mutation site to the premature stop codon at codon 203, in both patients 1 and 2 but not in their father. The autopsy of patient 1 showed remarkable prion protein (PrP) deposits in the sympathetic ganglion and peripheral nerves, correlated to her severe autonomic sensory failure. PrP deposits were also found in the central nervous system and peripheral organs such as the heart, lung, stomach, jejunum, ileum, colon, urinary bladder and adrenal gland. The symptoms and biopsy findings of patient 2 were nearly the same as those reported previously for patient 1. His cognitive function was well preserved, but autonomic functions were severely impaired. His biopsied samples showed PrP deposits in the sural nerve and nerve plexuses of the stomach and colon. CONCLUSION: The present unique 2-bp deletion (CT) in codon 178 induced a 'PrP systemic deposition disease' such as pan-autonomic failure, sensory neuropathy and mild cognitive impairment with a specific pathology.
  • Yusuke Fukui, Nozomi Hishikawa, Kota Sato, Taijun Yunoki, Syoichiro Kono, Kosuke Matsuzono, Yumiko Nakano, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Koji Abe
    Journal of the neurological sciences 357 (1-2) 178 - 82 0022-510X 2015/10 [Refereed][Not invited]
     
    OBJECTIVE: The purpose of this study was to clarify the difference between PSP and PD from the viewpoint of dynamic cerebrospinal fluid (CSF) flow focusing on the midbrain aqueduct. METHODS: Thirty-three PD patients (mean age 69.2±7.9) and 35 PSP patients (mean age 70.5±6.6) were included in this study. CSF flow was calculated by 15 images in an equidistant magnetic resonance imaging (MRI) sequence that was taken throughout a cardiac cycle. RESULTS: Absolute values of the velocity (time points of 2-6 and 12-15, *p<0.05), and the width of the CSF velocity (Vheight) (PSP, 5.1±2.3cm/s; PD, 6.0±1.6cm/s, p<0.05) effectively discriminated PSP from PD patients. On the other hand, conventional MRI measurements discriminated well the midbrain aqueduct area (Area) (PSP, 7.7±2.6mm(2); PD, 5.4±1.8mm(2), p<0.01). Two cutoff value lines (Vheight: 4.75, Area: 5.77) of the ROC curve analysis established two areas for discriminating PSP from PD. CONCLUSION: In the present dynamic CSF flow study, it was newly found that mean velocity of each time point and Vheight showed a more significant decline in PSP than in PD patients, providing a sensitive biomarker for differentiating them. The combination of Vheight and Area could further discriminate PSP from PD patients.
  • Yumiko Nakano, Kentaro Deguchi, Toru Yamashita, Ryuta Morihara, Kosuke Matsuzono, Yuko Kawahara, Kota Sato, Syoichiro Kono, Nozomi Hishikawa, Yasuyuki Ohta, Yasuto Higashi, Yoshiki Takao, Koji Abe
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 24 (7) 1621 - 8 1052-3057 2015/07 [Refereed][Not invited]
     
    BACKGROUND: This study investigated the incidence of current poststroke dementia (PSD), the annual conversion ratio into PSD, and the risk factors for conversion. METHODS: In a 4.8-year follow-up period, 112 poststroke patients (ischemic stroke and intracerebral hemorrhage) were retrospectively investigated in cognitive examinations. They were categorized into 3 subgroups: converters into PSD, nonconverters who maintained their normal cognitive functions, and reverters who recovered to the normal mentality range. The clinical and demographic characteristics of these 3 subgroups were analyzed. RESULTS: Among all 112 poststroke patients (61.6% male, 73.6 ± 10.4 years old), 16.1% had PSD. During the follow-up period, a part of the normal baseline mentality group (83.9% of 112 original patients) newly developed PSD (subdivided into converters) with an annual conversion rate of 7.6%. The reversion rate from the baseline PSD group was 11.3%. There were significant differences in age (P < .05), baseline mini-mental state examination scores (P < .05), body mass index (P < .05), and periventricular and deep white matter hyperintensity grades (P < .05 and P = .01, respectively) between converters and nonconverters. The annual rate of stroke recurrence was only 2.2% in all stroke subtypes. CONCLUSIONS: In comparison with stroke recurrence (2.2%), 7.6% of the annual PSD conversion rate was very high. Therefore, prevention of direct conversion into PSD without stroke recurrence may be another important aspect of poststroke clinics, especially in late elder society.
  • Tomoko Kurata, Violeta Lukic, Miki Kozuki, Daisuke Wada, Kazunori Miyazaki, Nobutoshi Morimoto, Yasuyuki Ohta, Kentaro Deguchi, Toru Yamashita, Nozomi Hishikawa, Kosuke Matsuzono, Yoshio Ikeda, Tatsushi Kamiya, Koji Abe
    Translational stroke research 6 (2) 107 - 15 1868-4483 2015/04 [Refereed][Not invited]
     
    Telmisartan is expected to reduce not only the level of blood pressure but also neuroinflammation and neurotoxicity via pleiotrophic effects as a metabo-sartan. We examined the effects of telmisartan on Alzheimer's disease (AD) pathology in spontaneously hypertensive rat stroke resistant (SHR-SR) after transient middle cerebral artery occlusion (tMCAO) by giving either telmisartan at 0 (vehicle), 0.3 mg/kg/day (low dose, with no reduction of blood pressure), or 3 mg/kg/day (high dose, with a significant reduction of blood pressure) p.o. from 3 months (M) of age, and performed immunohistological analysis at 6, 12, and 18 M of age. The numbers of amyloid β (Aβ)-positive neurons in the cerebral cortex and hippocampus and senile plaque (SP) in the ipsilateral cerebral cortex progressively increased with age until 18 M in the SHR-SR after tMCAO. On the other hand, low-dose telmisartan significantly reduced the number of Aβ-positive neuron as well as SP at 6, 12, and 18 M. High-dose telmisartan showed further reductions of the above AD pathology. The present study suggests that telmisartan reduced both intracellular Aβ and extracellular SP accumulations after tMCAO in SHR-SR, with a further improvement by combined BP lowering. Such a strong effect of telmisartan could provide a preventative approach for AD in post-stroke patients with hypertension.
  • Yasuhiro Manabe, Ryuta Morihara, Kosuke Matsuzono, Yumiko Nakano, Yoshiaki Takahashi, Hisashi Narai, Nobuhiko Omori, Koji Abe
    Neurology international 7 (1) 5973 - 5973 2035-8385 2015/03 [Refereed][Not invited]
     
    Small dense low-density lipoprotein (sdLDL) is an established risk factor in ischemic heart disease. However, its clinical significance in acute ischemic stroke (AIS) is uncertain. This study evaluates the prognostic value of the presence of sdLDL in patients with AIS by determining whether it contributes to clinical outcome or not. We studied 530 consecutive patients admitted within the first 48 hours after onset of ischemic stroke and 50 corresponding controls. Serum lipid parameters were measured on admission by standard laboratory methods. The percentage of AIS patients with sdLDL was significantly higher than the one of matched controls with sdLDL. Concerning comparisons between AIS patients with or without sdLDL, the percentages of males and patients with histories of smoking, hypertension, and cardiovascular disease were significantly higher in AIS patients with sdLDL. Concerning the grade of severity, modified Rankin Scale (mRS) on discharge was significantly higher in AIS patients with sdLDL. On logistic regression analysis, age (OR=2.29, P<0.001), male gender (OR=0.49, P<0.01), history of atrial fibrillation (OR=3.46, P<0.001), and the presence of sdLDL (OR=1.59, P<0.05) were significantly associated with poor prognosis (mRS on discharge >3). Our study showed that the presence of sdLDL might be independently associated with a poor prognosis after AIS.
  • K Abe, T Yamashita, N Hishikawa, Y Ohta, K Deguchi, K Sato, K Matsuzono, Y Nakano, Y Ikeda, Y Wakutani, Y Takao
    Journal of the neurological sciences 350 (1-2) 14 - 7 0022-510X 2015/03 [Refereed][Not invited]
     
    In addition to cognitive impairment, behavioral and psychological symptoms of dementia (BPSD) are another important aspect of most dementia patients. This study was designed for a new simple assessment of BPSD. We first employed a clinical survey for the local community with sending an inquiry letter to all members (n=129) of dementia caregiver society, and then attempted to create a new BPSD score for dementia with 10 BPSD items. This new simple BPSD score was compared to a standard-detailed BPSD score neuropsychiatric inventory (NPI) for a possible correlation (n=792) and a time to complete (n=136). Inter-rater reliability was examined comparing scores between main and second caregivers (n=70) for AD. Based on the clinical survey for local caregivers, a new BPSD score for dementia (ABS, Abe's BPSD score) was newly created, in which each BPSD item was allotted by an already-weighted score (maximum 1-9) based on the frequency and severity, and was finalized with taking temporal occurrences into account. ABS was filled by the main caregiver with a full score of 44, was well correlated with NPI (r=0.716, **p<0.01) in 792 AD patients (age 78.6 ± 7.0 years, MMSE 19.0 ± 5.9), and took a shorter time as only 56.8 ± 38.8s (**p<0.01) than NPI score (132.7 ± 94.0 s) with 136 AD patients. A high inter-rater reliability was obtained (r=0.964, **p<0.01) with a little smaller score (0.877 time) of ABS in secondary than the main caregivers. ABS provides a new simple and quick test for BPSD assessment, with a good correlation to NPI but a shorter time, and with a high inter-rater reliability. Thus ABS is useful for evaluating BPSD for mild to moderate dementia patients.
  • Kosuke Matsuzono, Chiaki Yokota, Hidehiro Takekawa, Tomonori Okamura, Naomi Miyamatsu, Hirofumi Nakayama, Kunihiro Nishimura, Satoshi Ohyama, Akiko Ishigami, Kosuke Okumura, Kazunori Toyoda, Yoshihiro Miyamoto, Kazuo Minematsu
    Stroke 46 (2) 572 - 4 0039-2499 2015/02 [Refereed][Not invited]
     
    BACKGROUND AND PURPOSE: Educating the youth about stroke is a promising approach for spreading stroke knowledge. The aim of this study was to verify communication of stroke knowledge to parents by educating junior high school students about stroke. METHODS: We enrolled 1127 junior high school students (age, 13-15 years) and their parents in the Tochigi prefecture, Japan. All students received a stroke lesson, watched an animated cartoon, and read the related Manga comic as educational aids. The students took back home the Manga and discussed what they learned with their parents. Questionnaires on stroke knowledge were given to all at baseline and immediately after the lesson. RESULTS: A total of 1125 students and 915 parents answered the questionnaires. In the students, the frequency of correct answers increased significantly for all questions on stroke symptoms except for headache, and for all questions on risk factors after the lesson. In the parents, the correct answer rates increased for stroke symptoms except for headache and numbness in one side of the body, and for all questions on risk factors except for hypertension. Ninety-one percent of students and 92.7% of parents correctly understood the Face, Arm, Speech, and Time (FAST) mnemonic after the lesson. CONCLUSIONS: Improvement of stroke knowledge immediately after the stroke lesson was observed in parents as well as their children, which indicated that our teaching materials using the Manga was effective in delivering the stroke knowledge to parents through their children.
  • Matsuzono K, Hishikawa N, Ohta Y, Yamashita T, Deguchi K, Abe K
    Neurology and Clinical Neuroscience 3 (5) 182 - 184 2049-4173 2015 [Refereed][Not invited]
     
    The primary clinical manifestations of synovitis, acne, pustulosis, hyperostosis and osteitis syndrome are skin lesions and osteitis. We describe a 53-year-old woman patient suffering from overlapping refractory headache and polyneuritis (cranial nerves I, II and VII). She complained of headaches, which recurred every month, followed by bilateral anosmia and left vision loss approximately 1 year later. Prednisolone therapy improved her symptoms; however, her refractory headache, pain in the right shoulder and left hip joint, and rash recurred 1 year after prednisolone withdrawal. Also, the patient presented with left sensorineural deafness and extensive acne on her body, and bone scintigraphy and bone biopsy showed synovitis, acne, pustulosis, hyperostosis and osteitis syndrome. After treatment, her symptoms improved without recurrence. Although synovitis, acne, pustulosis, hyperostosis and osteitis syndrome induced by polyneuritis is rare, it should be considered when clinicians encounter patients presenting with headache and polyneuritis of unknown cause.
  • umefactive demyelinating disease mimicking malignant tumor in positron emission tomography with 11C-methionine
    Matsuzono K, Deguchi K, Hishikawa N, Yamashita T, Date I, Ichikawa T, Abe K
    Neurology and Clinical Neuroscience 3 (2) 81 - 83 2015 [Refereed][Not invited]
  • Kosuke Matsuzono, Nozomi Hishikawa, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Yumiko Nakano, Koji Abe
    Journal of Alzheimer's disease : JAD 45 (3) 771 - 80 1387-2877 2015 [Refereed][Not invited]
     
    BACKGROUND/OBJECTIVE: To compare the effectiveness of combination therapy with cholinesterase inhibitors (ChEI) plus memantine in all AD patients and in older AD patients (age >75 years). METHODS: The Okayama Memantine Study was used to compare the clinical effects of combination therapy of donepezil plus memantine (n = 61) or galantamine plus memantine (n = 53) in all AD patients, and in older AD patients separately, with six batteries at baseline, at 6 months with ChEI only monotherapy, and at 3, 6, and 12 months after addition of memantine to the treatment schedule (18 months total). RESULTS: The addition of memantine resulted in stabilization of the Mini-Mental State Examination scores and Hasegawa dementia rating for 6 months, and then significantly declined at 12 months in both subgroups. Frontal assessment battery (FAB) declined significantly at 12 months after memantine addition in the donepezil subgroup, while the galantamine subgroup significantly improved at 6 months. Affective functions were well preserved after memantine addition until 12 months, except for the apathy scale at 12 months after memantine addition in the galantamine subgroup. The combination therapy of donepezil plus memantine was better for apathy in older AD patients, and galantamine plus memantine was better for cognitive functions. CONCLUSIONS: The addition of memantine stabilized cognitive scores for 6 months and affective scores for 12 months in the donepezil subgroup. Additionally, memantine significantly improved FAB at 6 months in the galantamine subgroup although apathy scale became significantly worse at 12 months.
  • Kosuke Matsuzono, Ryuta Morihara, Kota Sato, Nozomi Hishikawa, Toru Yamashita, Kentaro Deguchi, Koji Abe
    Internal medicine (Tokyo, Japan) 54 (1) 79 - 82 0918-2918 2015 [Refereed][Not invited]
     
    We experienced a unique case of familial prion disease with a prion gene mutation that caused pan-autonomic failure, sensory neuropathy and mild cognitive impairment. No abnormal sites of intensity were observed on diffusion-weighted magnetic resonance image (MRI) over six to 11 years or fluid attenuated inversion recovery MRI at six or nine years. However, (99m)Tc-ethylcysteinate dimer single photon emission computed tomography (SPECT) showed a decreased cerebral blood flow in the bilateral parietal and occipital lobes at nine years, which then expanded at 11 years, corresponding to mild atrophy in these areas on MRI. In some cases of prion mutations, particularly the slowly progressive type, SPECT may show abnormalities, while MRI does not.
  • Yusuke Fukui, Nozomi Hishikawa, Kota Sato, Syoichiro Kono, Kosuke Matsuzono, Yumiko Nakano, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Koji Abe
    Internal medicine (Tokyo, Japan) 54 (14) 1717 - 23 0918-2918 2015 [Refereed][Not invited]
     
    OBJECTIVE: The purpose of this study was to examine a new MRI technology, dynamic cerebrospinal fluid (CSF) flow, to examine sporadic cerebellar ataxia patients with cortical cerebellar atrophy (CCA) and multiple system atrophy-cerebellar type (MSA-C). METHODS: Nine CCA patients (3 men and 6 women; mean age: 64.2±6.9 years) and 31 MSA-C patients (13 men and 18 women; mean age: 62.7±6.8 years) were examined by a dynamic CSF flow analysis. All CSF flow data were evaluated by phase contrast-MRI using a 1.5T MRI scanner. The CSF flow was calculated by 15 images in the equidistant MRI sequence which was taken through a cardiac cycle. RESULTS: Compared with the CCA patients, the absolute values of the mean velocity of the MSA-C patients were significantly reduced at time points 5 (CCA, 0.24±0.14 cm/s; MSA-C, 0.13±0.11 cm/s; (*) p<0.05) and 13 (CCA, -0.60±0.37 cm/s; MSA-C, -0.31±0.17 cm/s; (**) p<0.01). Significant correlations in Spearman's rank correlation coefficient were also found in MSA-C patients between the disease duration and the difference between the maximum and minimum velocities (Vheight) (r=-0.429, (*) p<0.05), the minimum velocity of the CSF (Vmin) (r=0.486, (**) p<0.01) or the length of the minor axis of the pons (r=-0.529, (**) p<0.01). The linear regressions between the disease duration and Vheight or Vmin revealed a significant strong correlation only in the MSA-C patients. CONCLUSION: The present CSF flow study showed for the first time that Vheight and Vmin revealed good correlations with the disease duration in the MSA-C patients. Furthermore, the velocity of the prepontine CSF flow tended to decrease in the MSA-C patients compared with the CCA patients, suggesting that this particular CSF flow analysis may be a new surrogate marker for differentiating both types of cerebellar ataxia.
  • Kosuke Matsuzono, Toru Yamashita, Yasuyuki Ohta, Nozomi Hishikawa, Makoto Koike, Kota Sato, Syoichiro Kono, Kentaro Deguchi, Yumiko Nakano, Koji Abe
    Journal of Alzheimer's disease : JAD 47 (2) 487 - 93 1387-2877 2015 [Refereed][Not invited]
     
    The clinical benefits of memantine, depending on the baseline cognitive and affective conditions in real world dementia clinics, have not been completely examined. We performed the "Okayama Memantine Study II (OMS II)" to retrospectively evaluate the clinical effects of memantine monotherapy (n = 38) in Alzheimer's disease (AD) patients using seven batteries to assess dementia at the baseline, at 3, 6, and 12 months. Additionally, we divided 163 AD patients treated with memantine into two subgroups depending on the baseline cognitive score of the Mini-Mental State Examination (MMSE): the MMSE <15 group (n = 36) and the baseline MMSE ≥15 group (n = 127). We also analyzed 71 AD patients based on the baseline behavioral and psychological symptoms of dementia (BPSD) severity using Abe's BPSD score (ABS). Memantine monotherapy maintained cognitive functions until 6 months of treatment, but showed a decrease at 12 months ( *p <  0.05 versus baseline). However, memantine monotherapy greatly improved BPSD symptoms until 12 months ( *p <  0.05,  **p <  0.01) and maintained other affective functions as well as the activity of daily living. Memantine treatment showed similar effects, regardless of the baseline cognitive functions, but showed better effects on ABS for higher baseline cognitive functions. Memantine treatment greatly improved ABS depending on baseline BPSD severity. Our present OMS II showed that memantine monotherapy improved BPSD until 12 months. The higher baseline cognitive subgroup (MMSE ≥15) and the worse baseline BPSD subgroup were expected to show better effects with memantine.
  • Yumiko Nakano, Kosuke Matsuzono, Toru Yamashita, Yasuyuki Ohta, Nozomi Hishikawa, Kota Sato, Kentaro Deguchi, Koji Abe
    Journal of Alzheimer's disease : JAD 47 (3) 609 - 17 1387-2877 2015 [Refereed][Not invited]
     
    BACKGROUND: Alzheimer's disease (AD) is one of the most significant diseases affecting an increasingly aging society. OBJECTIVE: To determine the long-term efficacy of galantamine treatment in a Japanese population. METHODS: We performed "Okayama Galantamine Study (OGS)" to retrospectively analyze the clinical effects of galantamine in 279 AD patients using 7 batteries for assessing dementia at baseline, 3, 6, 12, and 24 months. We further analyzed the effects of galantamine based on gender and the severity of their baseline cognitive, affective, and activity of daily living (ADL) functions. RESULTS: In all 279 AD patients (80.6 ± 7.2 years old, MMSE 20.0 ± 4.5), cognitive functions were well preserved until 12 months and even frontal assessment battery improved after 12 months although Hasegawa dementia scale-revised finally worsened at 24 months ( *p <  0.05) with galantamine treatment. Affective and ADL functions were also well maintained after galantamine treatment with significant improvement of Geriatric Depression Scale scores at 3 months ( *p <  0.05). Subanalyses showed the better response to galantamine for male and lower baseline function subgroups. CONCLUSIONS: Our present study (OGS) revealed a long-term efficacy of galantamine in very elderly AD patients, and suggested a better efficacy for male and baseline lower cognitive, affective, and ADL functions.
  • Kosuke Matsuzono, Nozomi Hishikawa, Toru Yamashita, Yasuyuki Ohta, Kota Sato, Shoichiro Kono, Kentaro Deguchi, Ryuta Morihara, Koji Abe
    Journal of Alzheimer's disease : JAD 48 (1) 279 - 86 1387-2877 2015 [Refereed][Not invited]
     
    BACKGROUND/OBJECTIVE: To examine comprehensive clinical evaluations of frontotemporal dementia (FTD) patients compared with Alzheimer's disease (AD) patients. METHODS: We used eight batteries and the touch panel test to retrospectively analyze 41 FTD patients compared with 121 AD patients. Furthermore, 34 FTD and all 121 AD patients were evaluated with a frontotemporal dementia-Alzheimer's disease index (FA index), which we developed for novel diagnosis with magnetic resonance imaging. RESULTS: Frontal assessment battery, geriatric depression scale, and Abe's behavioral and psychological symptom of dementia score were significantly worse in FTD patients than in AD patients ( **p <  0.01 in FAB,  **p <  0.01 in the geriatric depression scale, and  ***p <  0.001 in Abe's behavioral and psychological symptom of dementia score), although there was no significant difference in the other five scores. The finding mistakes game score of the touch panel test was worse in FTD than in AD ( *p <  0.05). The receiver operating characteristic curve of the FA index showed 91.4% sensitivity and 89.3% specificity with the FA index ≤0.6015 to discriminate FTD from AD. CONCLUSION: Combining clinical scores, a computerized touch panel test, and the FA index will help to provide a more accurate diagnosis of FTD in contrast to AD.
  • Kosuke Matsuzono, Kota Sato, Syoichiro Kono, Nozomi Hishikawa, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Yumiko Nakano, Koji Abe
    Journal of Alzheimer's disease : JAD 48 (3) 757 - 63 1387-2877 2015 [Refereed][Not invited]
     
    BACKGROUND/OBJECTIVE: Alzheimer's disease (AD) is one of the most important diseases in an aging society, but the clinical effects of rivastigmine have not been fully examined in real world domestic clinics. METHODS: We performed the "Okayama Rivastigmine Study (ORS)" to retrospectively analyze the clinical effects of rivastigmine (n = 75) or donepezil (n = 71) on AD patients with seven dementia assessment batteries at the baseline, 3, 6, and 12 months. In addition, we divided the rivastigmine group into two subgroups at the baseline: the mild behavioral and psychological symptoms of dementia (BPSD) group (Abe's BPSD score (ABS) <6) and the severe BPSD group (6≤ABS). In these two subgroups, baseline scores and changes were also retrospectively analyzed until 12 months. RESULTS: Rivastigmine significantly improved the Mini-Mental State Examination score at 3 months (*p <  0.05 versus baseline) and at 6 months (*p <  0.05), the Frontal Assessment Battery (FAB) at 6 months (*p <  0.05), and ABS at 3 months (**p <  0.01) while donepezil only stabilized the three cognitive scores. On the other hand, the Geriatric Depression Scale and the Apathy Scale were stable until 12 months in both groups. Baseline BPSD severity-dependent analysis showed a small improvement of FAB at 6 months in the mild BPSD subgroup (*p <  0.05) and a great improvement of ABS at 3 months in the severe BPSD subgroup (**p <  0.01) in the rivastigmine group. CONCLUSIONS: Our present study showed that rivastigmine improved both cognitive and affective functions at 3 and 6 months, and suggested an advantage at 3 and 6 months compared to donepezil in real world dementia clinics.
  • Kosuke Matsuzono, Toru Yamashita, Yasuyuki Ohta, Nozomi Hishikawa, Kota Sato, Syoichiro Kono, Kentaro Deguchi, Yumiko Nakano, Koji Abe
    Journal of Alzheimer's disease : JAD 46 (3) 687 - 93 1387-2877 2015 [Refereed][Not invited]
     
    BACKGROUND/OBJECTIVE: There are few reports on the effects of anti-Alzheimer's disease (AD) drugs on older AD patients, and possible differences based on gender in a real world setting. METHODS: "Okayama Late Dementia Study (OLDS)" is a retrospective clinical cohort study focusing on older AD patients (n = 373; age≥75 years) treated with monotherapy donepezil (n = 55), galantamine (n = 222), rivastigmine (n = 63), or memantine (n = 33). The patients were evaluated as an entire group and separated by gender, using seven batteries for dementia assessment at baseline and at 3, 6, and 12 months of drug therapy. RESULTS: All four drugs preserved cognitive and affective functions until 12 months, except for Frontal Assessment Battery (FAB) with memantine ( *p <  0.05 versus baseline). Donepezil monotherapy significantly improved Hasegawa Dementia Rating Scale-Revised (HDS-R) at 3 months ( *p <  0.05), and memantine (3 and 6 months, *p <  0.05) and rivastigmine (3 months, **p <  0.01) improved Abe's Behavior and Psychological Symptom of Dementia Score (ABS), respectively. Activities of daily living (ADL) became significantly worse with galantamine at 12 months ( *p <  0.05). Male Mini-Mental State Examination scores became worse at 12 months with donepezil ( *p <  0.05), as did female Geriatric Depression Scale scores at 6 months ( *p <  0.05). Male HDS-R and ABS scores were preserved in the galantamine group until 12 months. Female ABS scores with memantine improved at 6 months ( *p <  0.05), while male ADL scores became worse with rivastigmine at 12 months ( *p <  0.05). CONCLUSION: OLDS revealed that anti-AD drugs were effective even for older AD patients, and the clinical benefits of each drug showed a small difference with regard to gender.
  • Kosuke Matsuzono, Tomoko Kurata, Shoko Deguchi, Toru Yamashita, Kentaro Deguchi, Koji Abe
    Neurological research 36 (10) 906 - 10 0161-6412 2014/10 [Refereed][Not invited]
     
    OBJECTIVE AND IMPORTANCE: Although ketogenic diet therapy is effective in refractory seizures in childhood, its effect on adult encephalitis with similar refractory seizures and prolonged encephalopathy has not been well reported. CLINICAL PRESENTATION: We report here a case of a 22-year-old man with acute encephalitis with refractory repetitive partial seizures (AERRPS). INTERVENTION: Partial seizures of the face developed to repeated generalized convulsions, which were refractory against anti-epileptic drugs and a high dose of propofol. After struggling for 9 months, he dramatically recovered after ketogenic diet therapy. CONCLUSION: Ketogenic diet therapy may be an important tool to help cure AERRPS.
  • Kosuke Matsuzono, Yasuhiro Manabe, Yoshiaki Takahashi, Hisashi Narai, Nobuhiko Omori, Koji Abe
    Case reports in neurology 6 (1) 134 - 8 2014/01 [Refereed][Not invited]
     
    We report a patient with acute cerebral infarction of the left paramedian thalamus, upper mesencephalon and cerebellum who exhibited ipsilateral oculomotor nerve palsy and contralateral downbeat nystagmus. The site of the infarction was considered to be the paramedian thalamopeduncular and cerebellar regions, which are supplied by the superior cerebellar artery containing direct perforating branches or both the superior cerebellar artery and the superior mesencephalic and posterior thalamosubthalamic arteries. Contralateral and monocular downbeat nystagmus is very rare. Our case suggests that the present downbeat nystagmus was due to dysfunction of cerebellar-modulated crossed oculovestibular fibers of the superior cerebellar peduncle or bilateral downbeat nystagmus with one-sided oculomotor nerve palsy.
  • Yuko Kawahara, Masami Ikeda, Kentaro Deguchi, Nozomi Hishikawa, Syoichiro Kono, Yoshio Omote, Kosuke Matsuzono, Toru Yamashita, Yoshio Ikeda, Koji Abe
    Internal medicine (Tokyo, Japan) 53 (20) 2281 - 90 0918-2918 2014 [Refereed][Not invited]
     
    OBJECTIVE: Cognitive and affective dysfunctions are important aspects for patients with multiple sclerosis (MS) and neuromyelitis optica (NMO). METHODS: We herein examined the cognitive and affective ability in MS (n=35) and NMO (n=10) patients using computerized touch panel-type screening tests. RESULTS: While MS patients and normal controls (NC1, n=40) did not significantly differ in their scores from the Hasegawa dementia scale-revised (HDS-R) or the frontal assessment battery, MS patients did score significantly lower on the mini-mental state examination (MMSE). In contrast, NMO patients did not differ from the normal control group 2 (NC2, n=15) in any of the three cognitive assessments. We also examined the affective ability and found that MS patients scored significantly higher on the apathy scale (AS) compared with the NC1 group, while NMO patients scored significantly higher on the geriatric depression scale (GDS) compared with the NC2 group. Although the GDS and AS scores did not correlate with any of the cognitive assessments among MS patients, the AS scores did correlate with the MMSE and HDS-R among NMO patients. Compared with normal controls, the times to complete the flipping cards and arranging pictures games were significantly longer for MS patients but not for NMO patients. CONCLUSION: These results indicate differences between some features of cognitive and affective dysfunctions between MS and NMO patients. Computerized touch panel-type screening tests may be a more useful and sensitive tool for the cognitive assessment of MS patients than NMO patients.
  • Kosuke Matsuzono, Yoshio Ikeda, Shoko Deguchi, Toru Yamashita, Tomoko Kurata, Kentaro Deguchi, Koji Abe
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 22 (8) e682-3  2013/11 [Refereed][Not invited]
     
    Takotsubo cardiomyopathy can induce cerebral embolic stroke because of intracardiac thrombosis, but the timing of cardiogenic embolism relating to takotsubo cardiomyopathy has not been well described. We evaluated a 71-year-old woman with takotsubo cardiomyopathy, who developed cardiogenic cerebral embolism after recovery of cardiac wall motion. Nevertheless, we treated her with anticoagulation therapy. The present clinical observation suggests that attention should be paid to the timing when takotsubo cardiomyopathy resolves against risk of cardiogenic cerebral embolism.
  • K Matsuzono, Y Ikeda, W Liu, T Kurata, S Deguchi, K Deguchi, K Abe
    European journal of neurology 20 (5) e67-9 - 9 1351-5101 2013/05 [Refereed][Not invited]
  • Kosuke Matsuzono, Tomoko Kurata, Shoko Deguchi, Toru Yamashita, Kentaro Deguchi, Yoshio Ikeda, Koji Abe
    Clinical medicine insights. Case reports 6 113 - 7 2013 [Refereed][Not invited]
     
    We report two cases of anti-glutamic acid receptor (anti-GluR) antibody-positive encephalitis in males with symptoms such as Parkinsonism, urinary retention, and paralytic ileus. Although non-herpetic encephalitis typically shows magnetic resonance imaging (MRI) lesions in the limbic system during early stages, the present cases showed MRI lesions during later stages in the bilateral claustrum and pons. In both cases, anti-GluRɛ2 and δ2 antibodies were later shown to be positive in the cerebrospinal fluid but negative in the serum. Although early detection of anti-GluR antibodies is essential, early treatment may be significantly more important.
  • Kosuke Matsuzono, Takao Yoshiki, Yosuke Wakutani, Yasuhiro Manabe, Toru Yamashita, Kentaro Deguchi, Yoshio Ikeda, Koji Abe
    Internal medicine (Tokyo, Japan) 52 (18) 2127 - 9 0918-2918 2013 [Refereed][Not invited]
     
    We herein report a 53-year-old female with repeated transient ischemic attack (TIA) symptoms including 13 instances of right hemiparesis that decreased in duration over 4 days. Two separate examinations using diffusion weighted image (DWI) in magnetic resonance imaging (MRI) revealed normal findings, but we observed that both Babinski and Chaddock signs were completely synchronized with her right hemiparesis. We were only able to diagnose this case of early stage TIA using clinical signs. This diagnosis was confirmed 4 days after the onset by the presence of abnormalities on the MRI. DWI-MRI is generally useful when diagnosing TIA, but a neurological examination may be more sensitive, especially in the early stages.
  • Shohei Fujimoto, Yasuhiro Manabe, Daiki Fujii, Yuko Kozai, Kosuke Matsuzono, Yoshiaki Takahashi, Hisashi Narai, Nobuhiko Omori, Kaori Adachi, Eiji Nanba, Ichizo Nishino, Koji Abe
    Internal medicine (Tokyo, Japan) 52 (21) 2461 - 4 0918-2918 2013 [Refereed][Not invited]
     
    We herein report a novel compound heterozygous mutation of the acid α-glucosidase (GAA) gene in a 23-year-old man with adult-onset Pompe disease. The patient was admitted for respiratory failure and a highly elevated serum level of creatine kinase (CK). His muscle pathology did not show typical vacuolated fibers; however, globular inclusion bodies with acid phosphatase (ACP) activity was observed. A molecular genetic analysis of the GAA gene revealed a novel compound heterozygous mutation, c.1544 T>A (M515K), combined with a previously reported mutation, c.1309 C>T (R437C). The presence of ACP-positive globular inclusion bodies is a useful diagnostic marker for adult-onset Pompe disease, even when typical vacuolated fibers are absent.
  • Koji Abe, Yoshihisa Tatsuoka, Koichi Narikawa, Miyuki Matsumura, Kousuke Matsuzono
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 101 (8) 2270 - 87 0021-5384 2012/08 [Refereed][Not invited]
  • Katsuhiro Nishino, Suguru Yamaguchi, Kousuke Matsuzono, Hiroyuki Yamamoto
    Early Detection and Rehabilitation Technologies for Dementia: Neuroscience and Biomedical Applications 307 - 311 2011 [Refereed][Not invited]
     
    In 1994, the whole-hand electrical neural stimulation technique was reported by Dimitijevic to be useful in facilitating the recovery of hand-motor control after spinal cord injury and stroke. The authors of this chapter replicated this work and determined the effectiveness of the technique in restoring fine hand movement in 7 chronic stroke cases. Prior to treatment with electrical stimulation, all patients received rehabilitation, either for three months (acute cases) or for at least one month (chronic cases), after which no remarkable improvements in hand control were seen. The patient group consisted of 5 females and 2 males. The stroke damage included brain hemorrhage in 5 cases, brain infarct in 1 case, and bled AVM in 1 case. Post-onset duration was between 3 and 44 months, and the ages of patients ranged from 11 to 65 years. The electrical stimulation was carried out according to the protocol previously reported by (Dimitrijevic, 1994). The results showed that the range of motion (ROM) was improved in 6 out of 7 cases, while fine movement of the hand was also improved in 4 cases. These improvements were observed a few days after the initiation of whole-hand electrical neural stimulation. In one chronic stroke case, the treatment resulted in an almost full recovery of hand control during the first 30 minutes of sub-threshold sensory stimulation, including pinching and grasping. This dramatic recovery led the authors to hypothesize that the responder would show no lesioning of the motor cortex on CT or MRI images. While more cases are needed to test the limitations of this modality and to determine the relationship between the level of recovery and the topology of CNS lesioning, this work illustrates the utility of this approach for improving motor control of the hand in chronic stroke patients. © 2011, IGI Global.

MISC

  • 心房細動合併脳梗塞急性期患者における大動脈弓部複合粥腫病変(CAPs)併存に関する研究
    鈴木 雅之, 小澤 美里, 三浦 久美子, 小澤 忠嗣, 松薗 構佑, 益子 貴史, 小出 玲爾, 藤本 茂, 田中 亮太  脳循環代謝  32-  (1)  86  -86  2020/11
  • 高齢社会における脳梗塞の実態と課題
    松薗 構佑, 益子 貴史, 小澤 忠嗣, 三浦 久美子, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 亀田 知明, 藤本 茂  日本老年医学会雑誌  57-  (Suppl.)  70  -70  2020/07
  • SLEの経過中に可逆性両側内頸動脈病変を呈し脳梗塞に至った46歳女性例
    薄井 美由, 益子 貴史, 鈴木 雅之, 松薗 構佑, 小澤 忠嗣, 三浦 久美子, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  臨床神経学  60-  (1)  80  -80  2020/01  [Not refereed][Not invited]
  • 脳梗塞急性期のLDLコレステロール値とスタチン使用の急性期再発への影響
    横瀬 美里, 三浦 久美子, 古谷 浩平, 鈴木 雅之, 阿南 悠平, 小澤 忠嗣, 松薗 構佑, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  臨床神経学  59-  (Suppl.)  S250  -S250  2019/11
  • 妊娠中のプロテインS欠乏症に伴い脳静脈洞血栓症を呈した症例の臨床的検討
    薄井 美由, 小澤 忠嗣, 金 蓮姫, 益子 貴史, 松薗 構佑, 丸山 慶子, 小亀 浩市, 小出 玲爾, 藤本 茂  臨床神経学  59-  (Suppl.)  S296  -S296  2019/11
  • 脳梗塞患者における大動脈弓部プラークおよび心房細動と急性期脳卒中再発との関連
    阿南 悠平, 小澤 忠嗣, 横瀬 美里, 古谷 浩平, 鈴木 雅之, 三浦 久美子, 松薗 構佑, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  臨床神経学  59-  (Suppl.)  S324  -S324  2019/11
  • 脳梗塞急性期のLDLコレステロール値とスタチン使用の急性期再発への影響
    横瀬 美里, 三浦 久美子, 古谷 浩平, 鈴木 雅之, 阿南 悠平, 小澤 忠嗣, 松薗 構佑, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  臨床神経学  59-  (Suppl.)  S250  -S250  2019/11  [Not refereed][Not invited]
  • 妊娠中のプロテインS欠乏症に伴い脳静脈洞血栓症を呈した症例の臨床的検討
    薄井 美由, 小澤 忠嗣, 金 蓮姫, 益子 貴史, 松薗 構佑, 丸山 慶子, 小亀 浩市, 小出 玲爾, 藤本 茂  臨床神経学  59-  (Suppl.)  S296  -S296  2019/11  [Not refereed][Not invited]
  • 脳梗塞患者における大動脈弓部プラークおよび心房細動と急性期脳卒中再発との関連
    阿南 悠平, 小澤 忠嗣, 横瀬 美里, 古谷 浩平, 鈴木 雅之, 三浦 久美子, 松薗 構佑, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  臨床神経学  59-  (Suppl.)  S324  -S324  2019/11  [Not refereed][Not invited]
  • 虚血性脳卒中急性期に治療介入したせん妄及び不眠に関する検討
    松薗 構佑, 益子 貴史, 小澤 忠嗣, 三浦 久美子, 鈴木 雅之, 古谷 浩平, 小澤 美里, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  Dementia Japan  33-  (4)  559  -559  2019/10
  • 42歳で3回目の再発発作を認めた難治頻回部分発作重積型急性脳炎の女性例
    松薗 構佑, 古谷 浩平, 三浦 久美子, 小澤 忠嗣, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  日本老年医学会雑誌  56-  (4)  575  -575  2019/10  [Not refereed][Not invited]
  • 破傷風治療中にタコツボ心筋症様の壁運動異常を合併した75歳女性例
    堀切 映江, 松薗 構佑, 古谷 浩平, 小澤 忠嗣, 益子 貴史, 小出 玲爾, 田中 亮太, 藤本 茂  臨床神経学  59-  (7)  469  -469  2019/07  [Not refereed][Not invited]
  • 発症初期に診断に難渋し、コイル塞栓術が奏功したStaphylococcus haemolyticusによる感染性心内膜炎に続発した細菌性脳動脈瘤の女性例
    五十嵐 丈之, 松薗 構佑, 檜垣 鮎帆, 難波 克成, 青山 泰, 石山 裕介, 古谷 浩平, 藤本 茂  臨床神経学  59-  (4)  218  -218  2019/04  [Not refereed][Not invited]
  • 片側優位の可逆性後頭葉白質脳症(PRES)の1例
    長岡 理沙, 阿南 悠平, 小澤 忠嗣, 三浦 久美子, 松薗 構佑, 益子 貴史, 小出 玲爾, 田中 亮太, 藤本 茂  日本内科学会関東地方会  649回-  68  -68  2019/03  [Not refereed][Not invited]
  • PLEKHG5遺伝子の複合ヘテロ塩基置換を認めた進行性運動感覚ニューロパチーの孤発例
    嶋崎 晴雄, 古谷 浩平, 横瀬 美里, 鈴木 雅之, 金 蓮姫, 小澤 忠嗣, 松薗 構佑, 益子 貴史, 小出 玲爾, 松浦 徹, 藤本 茂  臨床神経学  58-  (Suppl.)  S270  -S270  2018/12  [Not refereed][Not invited]
  • Isolated hand palsyを呈した脳梗塞 機能的MRIによる機能局在解析の検討
    古谷 浩平, 小澤 忠嗣, 大貫 良幸, 金 蓮姫, 横瀬 美里, 鈴木 雅之, 松薗 構佑, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 松浦 徹, 川合 謙介, 藤本 茂  臨床神経学  58-  (Suppl.)  S279  -S279  2018/12  [Not refereed][Not invited]
  • 心停止と呼吸停止を主徴とする孤発性成人発症型ネマリンミオパチーの1例
    八木澤 伯耶, 松薗 構佑, 古谷 浩平, 金 蓮姫, 小澤 忠嗣, 益子 貴史, 小出 玲爾, 田中 亮太, 西野 一三, 藤本 茂  日本内科学会関東地方会  646回-  47  -47  2018/11  [Not refereed][Not invited]
  • 鈴木 雅之, 桧垣 鮎帆, 難波 克成, 松薗 構佑, 古谷 浩平, 五十嵐 丈之, 金 蓮姫, 小澤 忠嗣, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  神経治療学  35-  (6)  S218  -S218  2018/11  [Not refereed][Not invited]
  • 嶋崎 晴雄, 益子 貴史, 古谷 浩平, 横瀬 美里, 鈴木 雅之, 金 蓮姫, 小澤 忠嗣, 松薗 構佑, 小出 玲爾, 松浦 徹, 藤本 茂  神経治療学  35-  (6)  S240  -S240  2018/11  [Not refereed][Not invited]
  • 松薗 構佑, 古谷 浩平, 五十嵐 丈之, 八木澤 伯耶, 金 蓮姫, 小澤 忠嗣, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 田中 亮太, 藤本 茂  臨床神経生理学  46-  (5)  408  -408  2018/10  [Not refereed][Not invited]
  • 経食道心エコーが診断に有用であった急性期マイナーストローク3症例
    古谷 浩平, 横瀬 美里, 鈴木 雅之, 小澤 忠嗣, 金 蓮姫, 松薗 構佑, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 藤本 茂  Neurosonology  31-  (増刊)  85  -85  2018/06  [Not refereed][Not invited]
  • 発症から5年後に出現した皮疹により診断に至った神経Sweet病の1例
    塩野谷 匠, 古谷 浩平, 金 蓮姫, 小澤 忠嗣, 松薗 構佑, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 藤本 茂  日本内科学会関東地方会  642回-  31  -31  2018/06  [Not refereed][Not invited]
  • Pure motor isolated finger palsyを呈した脳梗塞の70歳男性例
    平山 果歩, 横瀬 美里, 小澤 忠嗣, 金 蓮姫, 松薗 構佑, 益子 貴史, 小出 玲爾, 嶋崎 晴雄, 松浦 徹, 藤本 茂  臨床神経学  58-  (4)  249  -249  2018/04  [Not refereed][Not invited]
  • 下肢静脈瘤硬化療法に続発した奇異性脳塞栓症に対してrt-PA治療を施行した68歳女性例
    鈴木 雅之, 松薗 構佑, 新井 直人, 金 蓮姫, 小澤 忠嗣, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 松浦 徹, 藤本 茂  臨床神経学  58-  (1)  53  -53  2018/01  [Not refereed][Not invited]
  • Ocular flutterが再発の初期徴候であったびまん性大細胞型B細胞性リンパ腫の1例
    黒田 百恵, 古谷 浩平, 金 蓮姫, 小澤 忠嗣, 松薗 構佑, 益子 貴史, 小出 玲爾, 松浦 徹, 翁 家国, 藤本 茂  日本内科学会関東地方会  638回-  40  -40  2017/12  [Not refereed][Not invited]
  • 脳虚血症状の出現から2年以内の経過で両側内頸動脈閉塞に至った甲状腺機能亢進症合併類もやもや病の一例
    鈴木 雅之, 松薗 構佑, 金 蓮姫, 小澤 忠嗣, 益子 貴史, 嶋崎 晴雄, 小出 玲爾, 松浦 徹, 藤本 茂  脳循環代謝  29-  (1)  192  -192  2017/11  [Not refereed][Not invited]
  • 【脳梗塞の急性期治療 現状と課題】抗血栓療法(抗血小板療法・抗凝固療法)の現状と課題
    松薗 構佑, 藤本 茂  Medical Science Digest  43-  (11)  556  -559  2017/10  [Not refereed][Not invited]
     
    脳梗塞急性期の抗小板療法として、アスピリン160-300mg/日の投与の有効性が確立している。また、軽症脳梗塞および一過性脳虚血発作に対する21日間のクロピドグレル+アスピリンの併用療法も有益性と安全性が大規模臨床試験で示されている。一方、脳梗塞急性期に抗凝固療法を行うことを支持する明確なエビデンスはなく、直接作用型経口抗凝固薬の有益性について現在検討中である。オザグレルやアルガトロバンの使用は日本での臨床試験を基に「脳卒中治療ガイドライン2017」でグレードBと推奨されているが、海外の脳卒中治療ガイドラインの記載とは解離がある。(著者抄録)
  • 松薗 構佑, 阿部 康二  Mebio  33-  (3)  31  -41  2016/03  [Not refereed][Not invited]
  • 松薗 構佑, 阿部 康二, 井上 治久  日本臨床  74-  (3)  443  -450  2016/03  [Not refereed][Not invited]
  • 新しいBPSDスコア(阿部式BPSDスコア=ABS)の開発と評価者間信頼性の検討
    阿部 康二, 菱川 望, 松薗 構佑, 中野 由美子, 佐藤 恒太, 太田 康之, 出口 健太郎, 山下 徹  臨床神経学  55-  (Suppl.)  S367  -S367  2015/12  [Not refereed][Not invited]
  • 神経組織再生による脳卒中の新規治療 皮膚から直接誘導された新規神経幹細胞(iNSCs)は脳梗塞を治療しうるか?
    山下 徹, 松薗 構佑, 阿部 康二  脳循環代謝  27-  (1)  96  -96  2015/10  [Not refereed][Not invited]
  • 【ALSとパーキンソン病-最近の進歩-】ALSの疾患特異的iPS細胞研究
    松薗 構佑, 山下 徹, 阿部 康二, 井上 治久  BIO Clinica  30-  (8)  747  -751  2015/08  [Not refereed][Not invited]
     
    現在、筋萎縮性側索硬化症(Amyotrophic Lateral Sclerosis、ALS)は原因不明、根治療法のない神経難病の代表的疾患である。しかし、近年Transactive response DNA binding Protein of 43 kDa(TDP-43)やChromosome 9 open reading frame(C9orf72)などの発見が相次いでおり、その病態が徐々に明らかにされている。一方、2006年に誕生した人工多能性幹細胞(Induced Pluripotent Stem cells、iPS細胞)は様々な難病の研究に使用され、ALSに対してもiPS細胞を使用した多数の研究が行われている。本稿では(1)ALS患者由来のiPS細胞を使用した疾患再現モデルに関する研究、(2)疾患特異的iPS細胞を使用したALS創薬に関する研究、(3)ALSに対するiPS細胞移植に関する研究について概説し、今後のALSに対するiPS細胞を利用した研究の展望について述べる。(著者抄録)
  • アルツハイマー病患者におけるガランタミンの長期的効果(Okayama Galantamine Study;OGS)についての検討
    中野 由美子, 松薗 構佑, 山下 徹, 太田 康之, 菱川 望, 佐藤 恒太, 出口 健太郎, 阿部 康二  日本神経心理学会総会プログラム・予稿集  39回-  200  -200  2015/08  [Not refereed][Not invited]
  • ドネペジル内服中のアルツハイマー病患者に対する認知リハビリテーションの上乗せ効果 後ろ向きコホート試験における検討
    松薗 構佑, 佐藤 恒太, 河野 祥一郎, 菱川 望, 太田 康之, 山下 徹, 出口 健太郎, 阿部 康二  日本認知症ケア学会誌  14-  (1)  352  -352  2015/04  [Not refereed][Not invited]
  • 松薗 構佑, 菱川 望, 太田 康之, 山下 徹, 出口 健太郎, 阿部 康二  Anti-aging Science  6-  (3)  188  -188  2014/12  [Not refereed][Not invited]
  • 多発性硬化症および視神経脊髄炎における認知機能の検討
    河原 由子, 池田 雅美, 出口 健太郎, 菱川 望, 河野 祥一郎, 表 芳夫, 松薗 構佑, 山下 徹, 池田 佳生, 阿部 康二  臨床神経学  54-  (Suppl.)  S204  -S204  2014/12  [Not refereed][Not invited]
  • 世界初の汎自律神経+知覚神経障害性プリオン病の遺伝子異常
    松薗 構佑, 菱川 望, 太田 康之, 山下 徹, 出口 健太郎, 阿部 康二  脳循環代謝  26-  (1)  159  -159  2014/11  [Not refereed][Not invited]
  • タッチパネル式コンピュータを活用した脳梗塞既往患者の認知機能と画像所見の関連の検討
    出口 健太郎, 河野 祥一郎, 柚木 太淳, 松薗 構佑, 中野 由美子, 角田 慶一郎, 河原 由子, 幡中 典子, 武本 麻美, 太田 康之, 菱川 望, 山下 徹, 阿部 康二  脳循環代謝  26-  (1)  168  -168  2014/11  [Not refereed][Not invited]
  • 反復性けいれんを伴う重症脳炎に対するケトン療法の効果
    松薗 構佑, 菱川 望, 太田 康之, 山下 徹, 出口 健太郎, 阿部 康二  脳循環代謝  26-  (1)  182  -182  2014/11  [Not refereed][Not invited]
  • 軽度認知機能低下と末梢神経障害を若年に呈した世界初のプリオン蛋白遺伝子変異家族例
    松薗 構佑, 佐藤 恒太, 菱川 望, 山下 徹, 出口 健太郎, 阿部 康二  Dementia Japan  28-  (4)  513  -513  2014/10  [Not refereed][Not invited]
  • 宮城哲哉, 尾原知行, 古賀政利, 西村寿貴, 森林耕平, 松園構佑, 田中博明, 吉松淳, 豊田一則  臨床神経学  54-  (7)  602  -602  2014/07  [Not refereed][Not invited]
  • タッチパネル式スクリーニング検査を用いた多発性硬化症および視神経脊髄炎における認知機能の検討
    河原 由子, 池田 雅美, 出口 健太郎, 菱川 望, 河野 祥一郎, 表 芳夫, 松薗 構佑, 山下 徹, 池田 佳生, 阿部 康二  日本抗加齢医学会総会プログラム・抄録集  14回-  354  -354  2014/06  [Not refereed][Not invited]
  • 宮城 哲哉, 尾原 知行, 古賀 政利, 西村 寿貴, 森林 耕平, 松薗 構佑, 田中 博明, 吉松 淳, 豊田 一則  脳と循環  19-  (2)  149  -153  2014/05  [Not refereed][Not invited]
     
    発症初期の頭部MRAにて脳血管攣縮が目立たなかった産褥期可逆性脳血管攣縮症候群(RCVS)の2例を経験した。症例1は36歳女で、妊娠38週に自然経腟分娩で出産した。4時間後に突然の激しい前頭部痛が出現し、救急搬送となった。激しい頭痛を繰り返し、FLAIR画像にて右前頭葉内側と右後頭葉皮質に微小な皮質性クモ膜下出血、MRA画像にて左後大脳動脈末梢の狭窄を疑う病変を認めた。RCVSを疑いベラパミルの内服を開始した。雷鳴頭痛の再燃なく経過した。発症3ヵ月後の頭部MRAで血管攣縮は消失し、RCVSと診断した。症例2は29歳女で、妊娠39週に自然経腟分娩で出産した。1時間後に軽度の頭痛が出現したが消失した。産褥3日目に前後頭部から側頭部の激しい痛みが出現した。RCVSを疑いベラパミルの内服を開始したが軽度の頭痛を繰り返した。発症3ヵ月後のMRAで各血管病変は消失し、RCVSと診断した。
  • 高齢者認知症の診断と治療に有用な新しい簡易BPSDスコア(阿部式BPSDスコア=ABS)
    阿部 康二, 菱川 望, 山下 徹, 出口 健太郎, 中野 由美子, 松薗 構佑  日本老年医学会雑誌  51-  (Suppl.)  51  -51  2014/05  [Not refereed][Not invited]
  • XIVてんかん症候群(6)進行性ミオクローヌス転換を示す疾患 4)若年型Huntington病.
    松薗構佑, 阿部康二  日本臨牀別冊新領域別症候群シリーズ 神経症候群(第2版)Ⅵ~その他の神経疾患を含めて  31-  307  -310  2014  [Not refereed][Not invited]
  • 松薗 構佑, 出口 章子, 倉田 智子, 山下 徹, 出口 健太郎, 阿部 康二  Anti-aging Science  5-  (3)  229  -229  2013/12  [Not refereed][Not invited]
  • 前方および後方循環系脳梗塞に対するrt-PA静注療法の効果に関する臨床的検討
    真邊 泰宏, 香西 由子, 松薗 構佑, 高橋 義秋, 奈良井 恒, 大森 信彦  臨床神経学  53-  (12)  1542  -1542  2013/12  [Not refereed][Not invited]
  • 歩行可能症例に対するバクロフェン随注療法(ITB療法)スクリーニングとその結果
    奈良井 恒, 松薗 構佑, 高橋 義秋, 大森 信彦, 真邊 泰宏  臨床神経学  53-  (12)  1635  -1635  2013/12  [Not refereed][Not invited]
  • 出口 健太郎, 河野 祥一郎, 中野 由美子, 松薗 構佑, 香西 由子, 出口 章子, 山下 徹, 倉田 智子, 池田 佳生, 阿部 康二, 本村 政勝, 太田 潔江  神経治療学  30-  (5)  663  -663  2013/09  [Not refereed][Not invited]
  • 松薗 構佑, 池田 佳生, 佐藤 恒太, 香西 由子, 出口 章子, 倉田 智子, 森本 展年, 出口 健太郎, 阿部 康二  末梢神経  24-  (1)  80  -84  2013/06  [Not refereed][Not invited]
     
    プリオン蛋白遺伝子はCreuzfeldt-Jakob病の原因遺伝子として周知されているが、プリオン蛋白遺伝子が末梢神経障害の原因となり得ることについて考察された文献は少ない。「c.534_535delCT(p.Asp178fs)」によるプリオン蛋白遺伝子変異症例ではhereditary sensory and autonomic neuropathies type I(HSAN-I)の臨床像を認め、腓腹神経生検でのプリオン蛋白免疫染色において対照群と異なる特徴的な所見を示した。プリオン蛋白遺伝子変異は遺伝性ニューロパチーの原因になりうることが推察され、今後さらなる症例の集積と検討が必要である。(著者抄録)
  • 診断に苦慮したgliomatosis cerebri(GC)の1例
    香西 由子, 林 紗織, 涌谷 陽介, 高尾 芳樹, 松薗 構佑, 高井 洋樹, 戸井 宏行, 西村 広健  臨床神経学  53-  (5)  385  -385  2013/05  [Not refereed][Not invited]
  • 世界初のプリオン蛋白遺伝子変異により発症した感覚自律神経性ニューロパチーの症例
    松薗 構佑, 池田 佳生, 佐藤 恒太, 香西 由子, 出口 章子, 倉田 智子, 森本 展年, 山下 徹, 出口 健太郎, 松浦 徹, 阿部 康二  臨床神経学  53-  (5)  392  -392  2013/05  [Not refereed][Not invited]
  • SIADHを呈した抗アクアポリン4抗体関連脳症の1例
    出口 章子, 池田 佳生, 香西 由子, 松薗 構佑, 池田 雅美, 出口 健太郎, 森本 展年, 倉田 智子, 松浦 徹, 阿部 康二, 高橋 利幸  臨床神経学  53-  (1)  69  -69  2013/01  [Not refereed][Not invited]
  • 松薗 構佑, 池田 佳生, 佐藤 恒太, 香西 由子, 出口 章子, 倉田 智子, 森本 展年, 出口 健太郎, 阿部 康二  末梢神経  23-  (2)  400  -401  2012/12  [Not refereed][Not invited]
  • 現代日本に有用な新しいBPSDスコア作成を目指して
    松薗 構佑, 倉田 智子, 村岡 万梨絵, 薮中 裕子, 阿部 康二  臨床神経学  52-  (12)  1491  -1491  2012/12  [Not refereed][Not invited]
  • 阿部 康二, 立岡 良久, 成川 孝一, 松村 美由起, 松薗 構佑  日本内科学会雑誌  101-  (8)  2270  -2287  2012/08  [Not refereed][Not invited]
  • 髄液抗GluRε2及び抗GluRδ2抗体陽性脳炎の1例
    松薗 構佑, 池田 佳生, 香西 由子, 出口 章子, 倉田 智子, 森本 展年, 出口 健太郎, 松浦 徹, 阿部 康二  臨床神経学  52-  (6)  446  -446  2012/06  [Not refereed][Not invited]
  • 原発性胆汁性肝硬変に合併した多発筋炎の一例
    香西 由子, 池田 佳生, 出口 章子, 松薗 構佑, 出口 健太郎, 松浦 徹, 阿部 康二, 若林 宏, 池田 房雄  臨床神経学  52-  (6)  450  -450  2012/06  [Not refereed][Not invited]
  • 高CK血症を合併した視神経脊髄炎(NMO)の2例
    出口 章子, 出口 健太郎, 松薗 構佑, 香西 由子, 河野 祥一郎, 森本 展年, 池田 雅美, 池田 佳生, 松浦 徹, 阿部 康二, 高橋 利幸  臨床神経学  52-  (6)  448  -448  2012/06  [Not refereed][Not invited]
  • 岡山大学神経内科における特発性慢性肥厚性硬膜炎7例の検討
    香西 由子, 池田 佳生, 出口 章子, 松薗 構佑, 森本 展年, 高宮 資宜, 出口 健太郎, 山下 徹, 佐藤 恒太, 奈良井 恒, 真邊 泰宏, 松浦 徹, 阿部 康二  臨床神経学  52-  (5)  383  -383  2012/05  [Not refereed][Not invited]
  • 掌蹠膿疱症に合併した両側遠位の上肢筋力低下の1例
    松薗 構佑, 河野 祥一郎, 香西 由子, 森本 展年, 出口 章子, 出口 健太郎, 池田 佳生, 松浦 徹, 阿部 康二  臨床神経学  52-  (5)  386  -386  2012/05  [Not refereed][Not invited]
  • 当院における特発性低髄液圧症候群4例の検討
    出口 健太郎, 松薗 構佑, 香西 由子, 河野 祥一郎, 出口 章子, 森本 展年, 倉田 智子, 池田 佳生, 松浦 徹, 阿部 康二  日本頭痛学会誌  38-  (2)  256  -256  2011/11  [Not refereed][Not invited]
  • 家系内に他の発症者を認めないM232R変異陽性家族性プリオン病の1例
    松薗 構佑, 池田 佳生, 香西 由子, 出口 章子, 倉田 智子, 森本 展年, 出口 健太郎, 松浦 徹, 阿部 康二  NEUROINFECTION  16-  (2)  190  -190  2011/10  [Not refereed][Not invited]
  • 西野 克寛, 山口 卓, 松薗 構佑, 坂元 亮太  JNET: Journal of Neuroendovascular Therapy  4-  (4)  242  -242  2010/11  [Not refereed][Not invited]

Awards & Honors

  • 2019 令和元年度自治医科大学附属病院優秀指導医賞
  • 2019 第70回老年医学会関東甲信越地方会奨励賞
  • 2012 第23回日本末梢神経学会学術集会最優秀ポスター賞

Research Grants & Projects

  • プリオン遺伝子変異が原因の稀少神経難病に対するiPS細胞を用いた創薬研究
    日本学術振興会:科学研究費助成事業 若手研究
    Date (from‐to) : 2021/04 -2023/03 
    Author : 松薗 構佑
  • 非翻訳領域リピート病-SCA36-の多系統に渡る神経障害の病態解明
    日本学術振興会:科学研究費助成事業 若手研究
    Date (from‐to) : 2018/04 -2021/03 
    Author : 松薗 構佑
     
    本研究では、SCA36 (脊髄小脳変性症36型) における多系統の神経障害機序を解明することを目的としている。そのため、1) SCA36患者由来のヒトiPS細胞 (人口多能性幹細胞) を各種系統の神経細胞 (運動神経細胞、ドパミン産生細胞、大脳皮質細胞) に分化させ、その分化能及び遺伝子発現を解析する、2) SCA36患者由来のヒトiPS細胞を対象に新たな病態機序の可能性について検討する、3) SCA36疾患モデルマウスを作製し、その行動解析を行う、の3方向からの研究を予定していた。 平成31年度 (令和元年)は1) SCA36患者由来のヒトiPS細胞から運動神経細胞、ドパミン産生細胞、大脳皮質細胞と3系統への分化に成功した。2) 1)を発展させ、SCA36の病態機序の一部を解明した。さらに、3) SCA36疾患モデルマウスの作製を目指し、計画立案が完成した。そのため、平成31年度 (令和元年) は本研究を大いに推進させることが出来た一方で、新型コロナウイルスの蔓延により、各学会が中止、情報の発信や入手が不可能になるという予想外の事態に見舞われた。 新型コロナウイルス蔓延という予想外の事態が、研究の遂行にも一部支障を来している一方で、必要な研究成果は出ているので、令和2年度での研究の完了を目指す。
  • Clearing and drug discovery for the noble neurological relentless disease of the autonomic nerve failure by prion gene mutation
    令和2年度横山臨床薬理研究助成基金研究助成金
  • Clearing the ALS pathology by SCA36 analysis
    金原一郎記念医学医療振興財団:2020年度基礎医学医療研究助成金
  • Study for multiple system disturbance of the neurological relentless disease by SCA36 disease pathological model.
    平成31年度自治医科大学医学部研究奨励金


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.